Abstract 1413P
Background
The phase 2 LUMINOSITY trial (NCT03539536) of Teliso-V monotherapy has shown acceptable safety & promising efficacy in previously treated patients (pts) with c-Met OE, EGFR WT, NSq NSCLC. Interim PRO data are reported.
Methods
Pts received Teliso-V (1.9 mg/kg) Q2W. PROs were assessed using the European Organisation for Research and Treatment of Cancer quality of life (QOL) questionnaires in lung cancer (LC13) & palliative cancer care (C15-PAL). Time to deterioration (TTD) beyond meaningful change threshold (MCT; ≥10 points from baseline) & mean change from baseline (mCFB) were analyzed.
Results
59 pts were evaluated. Median no. of prior therapies was 1 (range 1–3); median follow-up was 81 d. The table shows median TTD. For cough, pain in chest, pain in other parts, & QOL domains where median TTD was not reached, mCFB analyses revealed initial trends toward improvement. Cough, pain in chest, & overall QOL improved beyond MCT in wk 41, 49, & 41, respectively; pain in other parts trended toward deterioration. mCFB analyses revealed trends toward improvement for the LC13 symptom of hemoptysis, and for alopecia, sore mouth. Peripheral neuropathy deteriorated beyond MCT; dysphagia showed no consistent time trend. For C15-PAL, mCFB trend improved for nausea and vomiting, dyspnea (improved beyond MCT in wk 41), pain, fatigue, emotional function, and insomnia over a sustained duration for ≥29 wk, then deteriorated. Appetite loss worsened initially but improved in wk 41. Constipation improved initially then trended toward deterioration in wk 41 & 45.
Conclusions
This interim analysis suggests extended TTD and trends toward improvement from baseline in key lung cancer symptoms, physical functioning, & QOL; and deterioration in peripheral neuropathy. Impact of Teliso-V monotherapy on PROs will also be assessed at LUMINOSITY trial conclusion and in the phase 3, TeliMET NSCLC-01 trial (NCT04928846). Table: 1413P
Time to deterioration in symptoms, functional domains, and QOL
Instrument | Domains | Event/N | Median TTD, wk (95% CI) |
LC13 | Cough | 7/59 | NR |
Dyspnea | 22/59 | 33 (12, NE) | |
Pain in chest | 9/59 | NR | |
Pain in arm/shoulder | 22/59 | 20 (12, 34) | |
Pain in other parts | 17/59 | NR | |
C15-PAL | QOL | 18/59 | NR |
Physical function | 20/59 | 43 (8, NE) |
NE, not estimable; NR, Kaplan-Meier curve did not reach 50%.
Clinical trial identification
NCT03539536.
Editorial acknowledgement
Medical writing support was provided by Joanne Franklin, PhD, CMPP, from Aptitude Health, The Hague, the Netherlands, and funded by AbbVie.
Legal entity responsible for the study
AbbVie.
Funding
AbbVie.
Disclosure
S. Lu: Financial Interests, Institutional, Research Grant: AstraZeneca, Hutchmed, Bristol Myers Squibb, Hengrui Medicine, BeiGene, Roche, Hansoh; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Hansoh; Financial Interests, Institutional, Speaker, Consultant, Advisor: AstraZeneca, Pfizer, Hutchmed, Zai Lab, GenomiCare Biotechnology (Shanghai), Yuhan, Menarini, InventisBio Co, Roche; Financial Interests, Institutional, Advisory Board: AstraZeneca, Roche, Mirati Therapeutics. J. Bar: Financial Interests, Institutional, Advisory Board: AbbVie, AstraZeneca, Bayer, BMS, Causalis, Eisai, MSD, Novartis, Roche, Takeda; Financial Interests, Institutional, Research Funding: Immunai, OncoHost, MSD, AstraZeneca. N. Girard: Financial Interests, Institutional, Research Grant: AstraZeneca, Amgen, Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Janssen, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Sivan, Trizell; Financial Interests, Institutional, Speaker, Consultant, Advisor: Bristol Myers Squibb, AstraZeneca, AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Janssen, Merck, Merck Sharp & Dohme, Mirati, Novartis, Pfizer, Roche, Sanofi, Sivan; Financial Interests, Institutional, Other: Roche; Financial Interests, Institutional, Leadership Role: International Thymic Malignancy Interest Group; Financial Interests, Personal, Other: AstraZeneca. Q. Xu, R. Sen, C. Ratajczak, S. Ng, S. Xia: Financial Interests, Institutional, Full or part-time Employment: AbbVie. D.R. Camidge: Financial Interests, Institutional, Speaker, Consultant, Advisor: AbbVie, Amgen, Astellas BioPharma, AnHeart Therapeutics, Apollomics, AstraZeneca, BeiGene, Bio-Thera, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Elevation Oncology, EMD Serono, GSK, Helsinn Therapeutics, Hengrui Pharmaceutical, Janssen, Kestrel Labs, Lilly, Mersana, Nuvalent, Inc., OnKure, Pfizer, Puma Biotechnology, Qilu Pharmaceutical, Ribon Therapeutics, Roche, Sanofi, Seattle Genetics, Takeda, Turning Point Therapeutics; Financial Interests, Institutional, Research Funding: Inivata (Inst).
Resources from the same session
1368P - LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Presenter: Charu Aggarwal
Session: Poster session 20
1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Presenter: Renaud Descourt
Session: Poster session 20
1370P - Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
Presenter: Jianhua Chang
Session: Poster session 20
1371P - First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
Presenter: Young Kyung Jeon
Session: Poster session 20
1372P - Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Presenter: Ben Solomon
Session: Poster session 20
1373P - Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
Presenter: Maurice Pérol
Session: Poster session 20
1374P - Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Presenter: Moritz Glaser
Session: Poster session 20
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Presenter: Frans Opdam
Session: Poster session 20
1377P - Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Presenter: Xiuning Le
Session: Poster session 20
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20